Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)

Miksad, R.Cicin, I.Chen, Y.Klumpen, H.Kim, S.Lin, Z.Youkstetter, J.2024-06-122024-06-1220190923-75341569-8041https://hdl.handle.net/20.500.14551/26785European-Society-for-Medical-Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer -- JUL 03-06, 2019 -- Barcelona, SPAIN[Abstract Not Available]eninfo:eu-repo/semantics/closedAccess[No Keywords]Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellulat carcinoma (HCC)Conference Object30134134Q1WOS:000475860200021